Clinical Trials Logo

Corneal Ectasia clinical trials

View clinical trials related to Corneal Ectasia.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04763785 Active, not recruiting - Cataract Clinical Trials

Development of a Keratoconus Detection Algorithm by Deep Learning Analysis and Its Validation on Eyestar Images

DKDA
Start date: May 11, 2021
Phase:
Study type: Observational

Monocentric clinical study to develop an imaging analysis algorithm for the Eyestar 900 to identify keratoconus corneas and improve biometry for intraocular lens calculations

NCT ID: NCT04698590 Active, not recruiting - Keratoconus Clinical Trials

Wavefront Guided Scleral Lenses for Keratoconus and Irregular Astigmatism

WFG Sclerals
Start date: January 15, 2021
Phase: N/A
Study type: Interventional

Aberrations are the spreading of light from a point focus. Aberrations of the eyes can be objectively evaluated with a wavefront aberrometer. Lower order aberrations such as defocus and astigmatism can be corrected with glasses and traditional/disposable soft contact lenses. Patients with ectatic corneal disease, such as keratoconus, or irregular astigmatism cause by surgery, trauma or disease, experience vision that is unlikely to be adequately corrected with glasses or disposable soft contact lenses due to higher order aberrations (HOA). HOA's cause halos, flare, glare, starbursts, doubling, smearing or ghosting of vision. Specialty contact lenses, such as scleral lenses, can be used to mask the irregularity of the cornea, reducing HOA's and improving vision. In many patients the resultant vision, though improved, still has some level of residual HOA's affecting the quality of vision. Custom scleral lenses with customized wavefront guided optics can be used to reduce residual HOA's and improve vision further. These lenses have been referred to as higher order aberration correcting scleral lenses or HOA correcting sclerals and wavefront guided scleral lenses or WFG sclerals.

NCT ID: NCT04667572 Active, not recruiting - Keratoconus Clinical Trials

Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

Start date: February 1, 2021
Phase: Phase 1
Study type: Interventional

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in Eyes With Corneal Thinning Conditions

NCT ID: NCT02883478 Active, not recruiting - Keratoconus Clinical Trials

Clinical and Structural Outcome of Conventional Versus Accelerated Corneal Collagen Cross-linking (CXL).

CXL
Start date: August 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Compare different corneal parameters and visual outcome of corneal collagen cross-linking (CXL) with conventional versus accelerated ultraviolet-A irradiation using riboflavin with hydroxypropyl methylcellulose.

NCT ID: NCT01464268 Active, not recruiting - Keratoconus Clinical Trials

Transepithelial Corneal Collagen Crosslinking for Keratoconus and Corneal Ectasia

Start date: November 2011
Phase: Phase 3
Study type: Interventional

Corneal collagen crosslinking (CXL) has been proposed as an effective method of reducing progression of both keratoconus and corneal ectasia after surgery, as well as possibly decreasing the steepness of the cornea in these pathologies. During previous studies of the CXL procedure, the surface epithelial cells have been removed. Transepithelial crosslinking in which the epithelium is not removed has been proposed to offer a number of advantages over traditional crosslinking including an increased safety profile by reducing the risk for infection as no epithelial barrier will be broken, faster visual recovery and improved patient comfort in the early postoperative healing period.

NCT ID: NCT01152541 Active, not recruiting - Keratoconus Clinical Trials

Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin

Start date: June 2010
Phase: Phase 3
Study type: Interventional

Corneal collagen crosslinking (CXL) has been proposed as an effective method of reducing progression of both keratoconus and corneal ectasia after surgery, as well as possibly decreasing the steepness of the cornea in these pathologies. During the CXL procedure, the central corneal thickness has been shown to significantly change. The investigator's believe that better maintenance of corneal thickness potentially could have benefits of better reproducibility of the crosslinking effect with improved predictability of results.

NCT ID: NCT01112072 Active, not recruiting - Keratoconus Clinical Trials

Corneal Collagen Crosslinking and Intacs for Keratoconus and Ectasia

CXL
Start date: April 2010
Phase: Phase 3
Study type: Interventional

This study will determine the efficacy of corneal collagen crosslinking (CXL) combined with Intacs for the treatment of keratoconus and corneal ectasia. The goal of CXL is to decrease the progression of keratoconus, while Intacs has been shown to decrease corneal steepness in keratoconus. This study will attempt to determine the relative efficacy of the two procedures either performed at the same session versus CXL performed 3 months after Intacs.